Overview We are a biopharmaceutical company with a mission of pioneering medicines that transform patients lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA (sotagliflozin): We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001062822-26-000050 | EDGAR | 49K words |
| 2025-03-07 | 2024-12-31 | 0001062822-25-000013 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001062822-24-000008 | EDGAR | — |
| 2023-03-03 | 2022-12-31 | 0001062822-23-000007 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001062822-22-000005 | EDGAR | — |
| 2021-03-12 | 2020-12-31 | 0001062822-21-000013 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001062822-20-000015 | EDGAR | — |
| 2019-03-15 | 2018-12-31 | 0001062822-19-000007 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001062822-18-000008 | EDGAR | — |
| 2017-03-06 | 2016-12-31 | 0001062822-17-000013 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001062822-25-000054 | EDGAR | 14K words |
| 2025-08-06 | 2025-06-30 | 0001628280-25-038340 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001062822-25-000029 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001062822-24-000060 | EDGAR | — |
| 2024-08-02 | 2024-06-30 | 0001062822-24-000046 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001062822-24-000024 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001062822-23-000058 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0001062822-23-000047 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001062822-23-000024 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001062822-22-000042 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001062822-22-000035 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001062822-22-000022 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001062822-26-000047 | EDGAR | 2K words |
| 2026-02-02 | 0001193125-26-033793 | EDGAR | — |
| 2026-01-29 | 0001193125-26-029514 | EDGAR | — |
| 2025-11-10 | 0001193125-25-274383 | EDGAR | — |
| 2025-11-06 | 0001193125-25-270020 | EDGAR | — |
| 2025-11-06 | 0001062822-25-000049 | EDGAR | — |
| 2025-08-06 | 0001062822-25-000042 | EDGAR | — |
| 2025-07-28 | 0001062822-25-000037 | EDGAR | — |
| 2025-07-03 | 0001062822-25-000035 | EDGAR | — |
| 2025-06-03 | 0001062822-25-000033 | EDGAR | — |
301 total filings indexed. 269 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001062822 |
| Ticker | LXRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.lexpharma.com |
| Listed | 2000-04-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report